Why We Do Research on Hemophilia
People with hemophilia can experience complications such as joint disease and inhibitors that can affect overall health. CDC collaborates with public and private organizations to conduct research to better understand hemophilia. Results from this research are used to implement prevention programs to help reduce complications and improve the quality of life.
CDC conducts research to:
- Learn more about the extent of bleeding disorders and risk factors for complications.
- Design and implement interventions that will help prevent complications.
- Create and deliver health promotion messages to help people make informed decisions about their own health care.
- Identify new genetic markers of risk factors through lab analysis.
Following are some areas of research in hemophilia:
Universal Data Collection System
One of the major challenges facing researchers and scientists who work on rare disorders such as hemophilia is lack of access to uniform health data. To address this issue and advance health research, CDC supports and coordinates a public health surveillance project, the Universal Data Collection (UDC) system. UDC is conducted through a national network of specialized hemophilia treatment centers (HTCs). Overall, about 85% of hemophilia patients who receive care in HTCs participate in UDC.
Through UDC, a consistent set of health-monitoring data is collected from people with hemophilia and other bleeding disorders. The data collected are used to determine rates and severity of disease complications, describe treatment and care patterns, assess quality of life, and determine health issues for further study.
UDC collects data from:
- People with hemophilia and people with rare bleeding disorders
- Women and girls with bleeding disorders
- Children under 2 years of age with bleeding disorders
- People with inhibitors
UDC also monitors the hemophilia population for blood-borne infections and stores blood specimens for future research on emerging infectious diseases.
People with hemophilia lack a protein that is necessary for normal blood clotting. As many as one third of people with hemophilia develop an antibody—called an inhibitor—to the blood products that they use to stop or prevent a bleeding episode. Treatment of bleeding becomes extremely difficult, and the cost of care can skyrocket. In addition, people with inhibitors are at increased risk for joint disease and other complications from bleeding resulting in a reduced quality of life. In the Inhibitor Study, researchers are looking at why some people develop inhibitors.
CDC hopes that better understanding the causes of inhibitors will help us learn how to prevent them. That knowledge could result in decreased health care costs and safer, more effective treatment products for people with hemophilia. If patients with a particular genetic makeup are less likely to develop an inhibitor with one treatment therapy than with another, there may be opportunities to tailor therapy to individual patients based on their genetic makeup. This research has important implications for other genetically engineered products used for other diseases such as diabetes, for which genetically altered insulin is already available.
CDC Hemophilia A and Hemophilia B Mutation Project (CHAMP and CHBMP)
Hemophilia is caused by changes (mutations) in the genes for clotting factors VIII and IX. These mutations result in a decrease in the amount of factor, which is necessary for normal blood clotting. A deficiency of factor VIII is called hemophilia A and a deficiency of factor IX is called hemophilia B. As part of the Inhibitor Study, the Centers for Disease Control and Prevention (CDC) has gathered a list of all of the mutations reported to cause hemophilia worldwide. More than 2,000 mutations have been reported in the factor VIII gene and more than 1,000 in factor IX. The mutation that a person has determines how much clotting factor is produced and how well it works. Knowing the mutation that a person with hemophilia has is important for genetic testing of family members. It also can help predict how likely it is that a person will develop an inhibitor. Future treatments for people with hemophilia might work better for some types of mutations than for others.
Range of Motion Study Among the General Population
People with hemophilia may develop chronic joint disease from repeated bleeding into their joints. Over time, the joint disease results in decreased mobility of the joints. People without hemophilia also lose mobility in their joints with aging. However, there are very few studies of joint mobility over time in people without hemophilia. To have a baseline with which to compare people with hemophilia, the joints of more than 600 people in the general population were measured as part of the normal range of motion study. Data from this study will provide a baseline to learn more about loss of mobility due to joint bleeding in people with hemophilia.
Healthy Weight Programs
Maintaining a healthy weight is particularly important for people with hemophilia. Those who are overweight are more likely to have decreased movement in their joints. In addition, the dosage of treatment product is determined by body weight. Therefore, overweight people with hemophilia need a larger dose of treatment product, resulting in a higher cost of care.
CDC is conducting research with health care providers at hemophilia treatment centers (HTCs) to better understand their level of awareness on issues of healthy weight. This project aims to determine:
- How BMI is measured and interpreted
- What actions are taken if a patient is at risk of being overweight or obese
- What perceptions HTC staff may have about healthy weight
- How HTC staff can influence a positive outcome for people who receive comprehensive care in an HTC
Evaluation of the National Hemophilia Foundation’s National Prevention Program
The purpose of this study is to evaluate the National Hemophilia Foundation’s (NHF) National Prevention Program, developed in 2000 to help people with bleeding disorders prevent or reduce the complications of those disorders. The results of this study will be compared with data gathered in CDC’s national baseline study conducted in 1999–2000. That survey focused on knowledge about, attitudes toward, and behaviors associated with key prevention activities among youth and adults with hemophilia.
Additionally, this study will collect information about the dissemination of the national Do the 5! prevention campaign messages and assess the message recall of consumers. Both evaluations were conducted by Macro International through a telephone survey targeting adult men with hemophilia, parents of sons with hemophilia aged 9 years or younger, and youth aged 13–21 with hemophilia. Through this evaluation, CDC will learn more about the impact of the National Prevention Program and the extent that target audience members are aware of and able to recall the prevention messages of the Do the 5! campaign.
- Centers for Disease Control and Prevention
National Center on Birth Defects and Developmental Disabilities
Division of Blood Disorders
1600 Clifton Road
Atlanta, GA 30333
TTY: (888) 232-6348
New Hours of Operation